Printer Friendly

Browse Gastroparesis topic

 

Articles

1-70 out of 70 article(s)
Title Author Type Date Words
Global Gastroparesis Drugs Market Expected to Reach USD 6,486m by 2022, Allied Market Research Forecasts. Dec 6, 2017 479
Analysis of the Relationship between Helicobacter pylori Infection and Diabetic Gastroparesis. Huang, Ju Nov 18, 2017 3746
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis. Clinical report Aug 2, 2017 2482
Research Survey Reveals Unmet Needs of People With Gastroparesis. Aug 1, 2017 656
Diabetic Gastroparesis Forecast in 12 Major Markets 2017-2027: Risk Factors, Disease Diagnosis and Prognosis Along with Specific Variations by Geography and Ethnicity - Research and Markets. Jun 13, 2017 498
Diabetic Gastroparesis Forecast in 12 Major Markets 2017-2027: Risk Factors, Disease Diagnosis and Prognosis Along with Specific Variations by Geography and Ethnicity - Research and Markets. Jun 13, 2017 458
Speakers discuss diagnosis and management of Gastro paresis, GERD, Functional GI Disorders and Constipation. Report May 15, 2017 774
Global Gastroparesis Drugs Market to Grow at a CAGR of 3.5% by 2021 - Fast Track Approvals & Acquisitions to Change the Phase of the Market - Research and Markets. May 15, 2017 539
Global Gastroparesis Drugs Market to Grow at a CAGR of 3.5% by 2021 - Fast Track Approvals & Acquisitions to Change the Phase of the Market - Research and Markets. May 15, 2017 579
United Kingdom : Gastroparesis Drugs Market Trends, Drivers, and Growth Prospects until 2021. May 9, 2017 339
Global Gastroparesis Drugs Market 2017-2021. May 8, 2017 586
Global Market Study on Diabetic Gastroparesis Treatment : Drugs Product Type Segment Expected to Account for Maximum Revenue Share by 2024. Nov 2, 2016 793
Diabetic Gastroparesis Treatment Market Worth US$ 3,769.3 Mn by 2024: PMR Research. Sep 29, 2016 640
Global Diabetic Gastroparesis Treatment Market is Expected to Reach US$ 3,769.3 Mn by 2024 - PMR. Sep 22, 2016 835
Global Diabetic Gastroparesis Treatment Market is Expected to Reach US$ 3,769.3 Mn by 2024 - PMR. Sep 22, 2016 827
Learn the Facts about Gastroparesis. Aug 1, 2016 494
Japan : Takeda to Partner with Altos Therapeutics to Develop Promising Compound for the Treatment of Gastroparesis. Jul 5, 2016 436
"Diabetic Gastroparesis Global Clinical Trials Review, H1, 2016" Published. Jun 29, 2016 516
Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis. Apr 4, 2016 523
Cairn Diagnostics Launches FDA-Approved Spirulina Gastric Emptying Breath Test for Gastroparesis. Mar 29, 2016 918
Gastroparesis Pipeline Researched for H2 2015 in New Report. Oct 23, 2015 835
Gastroparesis Pipeline Researched for H2 2015 in New Report. Oct 23, 2015 829
New Market Research Report: Diabetic Gastroparesis - Pipeline Review, H2 2015. Oct 19, 2015 415
Gastroparesis - Pipeline Review, H2 2015 - New Study Released. Oct 18, 2015 484
Gastroparesis is a Hidden Medical Condition for Many. Jul 30, 2015 738
Market Report, "Diabetic Gastroparesis Global Clinical Trials Review, H1, 2015", published. Jul 28, 2015 459
Evoke Pharma awarded EU formulation patent for EVK-001 for gastroparesis. Apr 10, 2015 166
Evoke Pharma awarded EU formulation patent for EVK-001 for gastroparesis. Apr 10, 2015 162
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis. Apr 8, 2015 1807
Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis. Apr 8, 2015 1586
Just Published: "Gastroparesis - Pipeline Review, H1 2015". Mar 26, 2015 557
Gastroparesis--a novel cause of persistent thyroid stimulating hormone elevation in hypothyroidism. Khraisha, O.S.; Al-Madani, M.M.; Peiris, A.N.; Paul, T.K. Clinical report Mar 1, 2015 1745
Wernicke's encephalopathy as a complication of gastroparesis after emergency partial antrectomy. Ganie, N.S.; van Rensburg, E. Janse Clinical report Feb 1, 2015 1465
Ironwood Pharmaceuticals doses diabetic gastroparesis patient under Phase IIa clinical study of IW-9179. Clinical report Dec 10, 2014 255
Ironwood Pharmaceuticals doses diabetic gastroparesis patient under Phase IIa clinical study of IW-9179. Clinical report Dec 10, 2014 251
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule. Sep 10, 2014 165
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule. Sep 10, 2014 161
Lack of Awareness of Gastroparesis May Impact Medical Care. Aug 26, 2014 521
Targacept begins Phase 1/2 exploratory study of TC-6499 in diabetic gastroparesis patients. Jun 26, 2014 229
Targacept begins Phase 1/2 exploratory study of TC-6499 in diabetic gastroparesis patients. Jun 26, 2014 225
Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis. May 6, 2014 1065
New Report Available: Diabetic Gastroparesis - Pipeline Review, H1 2014. Feb 24, 2014 498
New Report Available: Diabetic Gastroparesis - Pipeline Review, H2 2013. Aug 7, 2013 458
Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. Clinical report May 20, 2013 1173
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes. Financial report May 20, 2013 625
Research and Markets: Diabetic Gastroparesis Global Clinical Trials Review, H1, 2013 Provides Briefing Pertaining To the Number of Trials for the Key Drugs. Mar 5, 2013 332
Theravance Inc and Alfa Wassermann SpA partnership initiates Phase 2 gastroparesis study of velusetrag. Jan 9, 2013 206
Theravance Inc and Alfa Wassermann SpA partnership initiates Phase 2 gastroparesis study of velusetrag. Jan 9, 2013 202
Theravance Inc partners with Alfa Wassermann to develop and commercialise Velusetrag for gastroparesis. Oct 3, 2012 241
Theravance Inc partners with Alfa Wassermann to develop and commercialise Velusetrag for gastroparesis. Oct 3, 2012 237
Research and Markets: Diabetic Gastroparesis Global Clinical Trials Review, H1, 2012. Jun 6, 2012 342
Research and Markets: Gastroparesis - Pipeline Review, H1 2012. May 18, 2012 420
Research and Markets: Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019. May 4, 2012 405
Tranzyme begins dosing in Phase IIb study of TZP-102 in diabetic gastroparesis. Oct 5, 2011 124
Research and Markets: Diabetic Gastroparesis - Pipeline Review, Q3 2011. Aug 31, 2011 304
Research and Markets: Gastroparesis - Pipeline Review, Q2 2011: a Snapshot of the Global Therapeutic Scenario. Jun 9, 2011 322
Gastroparesis. Gregg, Karen Hein Disease/Disorder overview Nov 1, 2010 1093
Tranzyme Pharma Announces Positive Results from Phase 2 Study of Oral TZP-102 (Ghrelin Agonist) in Patients with Diabetic Gastroparesis. Clinical report Jun 29, 2010 790
Electroacupuncture effects on diabetic patients with gastroparesis. Robertshawe, Penny Report Mar 1, 2010 630
Salix Receives FDA Marketing Approval for METOZOLV[TM] ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD. Sep 8, 2009 1645
Tranzyme Pharma Initiates Dosing in a Phase 2 Study of its Oral Ghrelin Agonist TZP-102 in Patients with Gastroparesis. Clinical report May 5, 2009 435
Tranzyme Pharma Announces Positive Phase 2 Results with TZP-101 for Improvement of Symptoms in Patients with Gastroparesis. Financial report Apr 22, 2009 835
Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis. Clinical report Oct 30, 2007 746
Step-down Tx helpful in refractory gastroparesis. Boschert, Sherry Oct 15, 2006 569
Electrical stimulation aids chronic gastroparesis. Boschert, Sherry Oct 15, 2006 578
Pilot study on gastric electrical stimulation on surgery-associated gastroparesis: long-term outcome. Abell, Thomas L. Jul 1, 2005 3160
Many gastroparesis patients affected by coagulopathies. Zoler, Mitchel L. Apr 15, 2005 322
Gastric stimulation device may curb hunger: potential weight loss tool. Splete, Heidi Dec 1, 2003 705
Device limits vomiting in refractory gastroparesis. (AIDS Glycosylated Hemoglobin Measures). Jancin, Bruce Jan 15, 2003 683
Hospitalizations and outcomes for diabetic gastroparesis in North Carolina. Summerson, John H. Nov 1, 2002 1905

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters